Gts Securities LLC Viking Therapeutics, Inc. Call Options Transaction History

Gts Securities LLC

4 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q2 2024 Aug 14, 2024	SELL	$47.39 - $80.2 $8.67 Million - $14.7 Million	-182,900 Reduced 69.44%	80,500 $4.27 Million
Q1 2024 May 15, 2024	BUY	$17.4 - $94.5 $861,299 - $4.68 Million	49,500 Added 23.14%	263,400 $21.6 Million
Q4 2023 Feb 14, 2024	BUY	$9.24 - $19.64 $1.2 Million - $2.55 Million	129,600 Added 153.74%	213,900 $3.98 Million
Q3 2023 Nov 15, 2023	BUY	$10.92 - $16.0 $920,556 - $1.35 Million	84,300 New	84,300 $933,000

464

65.3M

6.24M

2.97M

Ticker VKTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 76,688,496
Market Cap $5.71B
Description
Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trial...

Get notified when there are updates to the investment portfolio of Gts Securities LLC, based on Form 13F filings with the SEC.

Stay updated on Gts Securities LLC with notifications on news.